Better Buy: Green Thumb Industries vs. Curaleaf Holdings
The article compares U.S. multi-state cannabis operators Green Thumb Industries (GTBIF) and Curaleaf Holdings (CURLF). It says Curaleaf is the largest MSO by TTM sales (~$1.3B) versus Green Thumb (~$1.2B). Both face regulatory and tax uncertainty under IRS Section 280E. Green Thumb has positive GAAP EPS for five years and trades at ~3.5x EV/EBITDA versus Curaleaf ~15.5x, while Curaleaf targets Europe and plans an OTC-to-exchange uplisting pending approval.
How this was made
The 30-second read
Why it matters
The key tradable risk is the IRS’s unresolved stance on whether these companies are subject to Section 280E; the key tradable catalyst for Curaleaf is an OTC-to-major-exchange uplisting pending regulatory approval plus Europe expansion.
Market read
This is a comparative, catalyst-and-risk framing piece: GTBIF is positioned as more value/fundamentals but exposed to IRS 280E risk; CURLF is positioned for momentum via uplisting and international expansion.
What to watch
GAAP unprofitability for Curaleaf and the lack of a confirmed IRS decision date for 280E could dominate near-term trading more than the long-term narrative.
Background
Both Green Thumb and Curaleaf operate as multi-state operators in a US cannabis industry still not fully legalized federally; Section 280E limits deductions for Schedule I/II controlled substances.
Ticker impact
Article contrasts Green Thumb’s valuation and profitability with the key risk that the IRS could reject its position on Section 280E tax treatment.
Near-term price sensitivity likely tied to any incremental regulatory/tax interpretation headlines rather than fundamentals alone.
The piece is comparative and opinion-led, but it highlights a specific, binary regulatory/tax overhang (IRS decision on 280E) that can re-rate risk.
Article highlights Curaleaf’s catalysts: pursuing licensed cannabis in Europe and planning an OTC-to-major-exchange uplisting pending regulatory approval.
If uplisting odds improve or regulatory signals emerge, CURLF could see outsized momentum versus peers; otherwise it may fade back to valuation/risk.
The article specifies two actionable catalysts (Europe expansion and uplisting pending approval) but provides no new regulatory decision or concrete timeline.
Market effects
Reinforces that US MSO equity risk is dominated by federal tax/regulatory interpretation (Section 280E) and by liquidity catalysts (uplisting).
Europe licensing is cited as a diversification lever for Curaleaf, implying potential demand/earnings optionality outside the US.
Highlights cross-border regulatory arbitrage as a valuation driver for cannabis operators with international footprints.
Counterpoint
The article’s “better positioned” framing may over-weight speculative catalysts (uplisting, Europe) while under-weighting the probability/timing risk of regulatory approvals.
Key entities
- regulatorInternal Revenue Service (IRS)
Haven’t made a final decision on whether MSOs are subject to Section 280E, creating potential tax-liability risk.
- regulationSection 280E
Tax rule restricting deductions for businesses selling Schedule I/II controlled substances; outcome affects after-tax earnings.
- strategyCuraleaf Europe expansion
Pursuing opportunities in Europe’s licensed cannabis market as a diversification catalyst.
- corporate_actionCuraleaf uplisting plan
Plans to move its primary listing from OTC to a major exchange, pending regulatory approval.
